Beijing tricision Biotech Co., Ltd. (tricision) and China Resources Biopharmaceutical Co., Ltd. (China Resources Biopharmaceutical) have announced that Yixing Chenggong New Drug Development Co., Ltd. (Chenggong New Drug), a wholly-owned subsidiary of tricision, has entered into a strategic cooperation agreement with China Resources Biopharmaceutical for the co-development of an mRNA Respiratory Syncytial Virus (RSV) vaccine.

The partnership, founded on principles of mutual benefit, complementarity, and innovation, leverages tricision's proven capabilities in its clinically validated plasmid and Messenger RNA (mRNA) platforms, nanotechnology and delivery systems, and Chemistry, Manufacturing, and Controls (CMC) platform, combined with China Resources Biopharmaceutical's industry-leading position and clinical development expertise. Together, the two parties will pursue deep collaboration on prophylactic mRNA vaccines for infectious diseases.

RSV: A Persistent Global Health Challenge

Respiratory Syncytial Virus (RSV) is a negative-sense, single-stranded RNA virus belonging to the genus Pneumovirus of the family Paramyxoviridae. First isolated from chimpanzees in 1956, it was named for its association with respiratory infections and its ability to fuse infected cells. RSV imposes a significant disease burden on infants, young children, and the elderly. Treatment for high-risk populations is primarily symptomatic and supportive, making prevention the cornerstone of RSV management. Natural infection does not induce durable immune memory against conserved immunogens, so RSV immunoprophylaxis relies on passive prevention (antibody drugs) or active prevention (prophylactic vaccines). Despite more than 60 years of research, no broadly effective preventive or therapeutic agent has been approved globally.

Differentiated Technology: tricision's mRNA RSV Vaccine Candidate

The RSV vaccine being co-developed by Chenggong New Drug and China Resources Biopharmaceutical is built on tricision's immunology-driven plasmid platform, which has undergone extensive screening and optimization. The vaccine is produced using the clinically validated mRNA platform, with formulation optimization via nanotechnology and the Lipid Nanoparticle (LNP) platform, and rapid pilot-scale production through the CMC platform. The nanoliposome C2 molecule employed—tricision's proprietary patented liposome—features a unique spatial structural design that offers advantages including structural stability, safety, and high membrane fusion efficiency. Recent analytical data indicate that this mRNA RSV vaccine demonstrates significant technical and market advantages in safety and efficacy compared to various international RSV vaccine products.

Building on an Existing Collaboration

This strategic cooperation between China Resources Biopharmaceutical and tricision follows their previous collaboration in January 2023 on therapeutic drug co-development for Glioblastoma Multiforme (GBM), marking a second strategic partnership—this time on mRNA vaccine R&D and commercialization for RSV. Both projects represent globally challenging research areas, entailing significant scientific hurdles, but also substantial opportunities and long-term promise.

Integrated Platform Advantage

tricision's core "One Body, Two Wings" technology architecture—comprising nucleic acid technology, Nanodelivery Platform (NP), and Cell Delivery Platform (CDP)—along with over 40 patented technologies including triVAC, C2 liposome, mRNA lyophilization technology, and Needle-Free Injection (NFI), enables rapid product development while also offering platform advantages in product design, process development, stability, safety, and high delivery efficiency.

As the innovative biologics platform of the China Resources Pharmaceutical Group, China Resources Biopharmaceutical's renewed collaboration with tricision aims to accelerate the domestic R&D and market launch of mRNA nucleic acid drugs, ensuring that innovative technologies and therapies enter the market safely and effectively, safeguarding public health, and jointly advancing China's innovative biopharmaceutical development.